1.	Efficacy and Safety of BI 2536 in Advanced or Metastatic Non Small Cell Lung Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1216.9, NCT00376623
2.	BI 2536 Second Line Monotherapy in SCLC Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 1216.11, NCT00412880
3.	BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CDR0000561067, EORTC-90061, EUDRACT-2006-004529-27, EORTC-90061-BI 1216.18, NCT00526149
4.	BI 2536 Infusional Treatment in Patients Over 60 Years of Age With Refractory or Relapsed Acute Myeloid Leukaemia Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: Over 60 Sponsor: Pharmaceutical / Industry Protocol IDs: 1216.20, EudraCT No:2006-000613-38, NCT00701766
5.	BI 2536 as Monotherapy in Treatment of Relapsed and Refractory Lymphoma Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CDR0000446176, BOEH-BI-1216.3, UNMC-16005, NCT00243087